One stem cell treatment stabilizes macular degeneration, another blinds 3 patients

(CNN) As we grow older, a common disease called macular degeneration can threaten our eyesight. An experimental stem cell treatment proved effective at halting this disease with no serious side effects up to a year later, a study published Wednesday in the New England Journal of Medicine found. It is the first treatment using personalized, genetically [...]

2021-11-07T17:53:41+00:00March 17th, 2017|

The Macula Vision Research Foundation (MVRF) & VisionCare, Inc. Announce Partnership to Increase Awareness of Treatments for Age-Related Macular Degeneration

The Macula Vision Research Foundation (MVRF) and VisionCare, Inc. have formed a unique partnership of industry and philanthropy to benefit more than 15 million people in the United States with age-related macular degeneration (AMD). The goal of this partnership is to increase awareness of potential treatments for AMD including the CentraSight treatment program, which includes [...]

2021-11-07T17:53:41+00:00March 9th, 2017|

Researchers Develop Best-Yet Cell Culture System for Age-Related Macular Degeneration

An international team from the University of Alabama at Birmingham and University College London and Queens University Belfast in the United Kingdom developed a cell culture model that could help to develop earlier treatment strategies for age-related macular degeneration, the third most prevalent cause of vision loss worldwide. In AMD, which is twice as prevalent [...]

2021-11-07T17:53:42+00:00February 22nd, 2017|

Clinical Trial Update: Squalamine Eye Drops for Wet Macular Degeneration

Many readers have been following closely the development of Squalamine Eye Drops for wet age-related macular degeneration, hoping that a self-administered at-home eye drop could reduce, or even eliminate, the need for monthly or as-needed eye injections. Unfortunately, a clinical trial designed to test this concept has produced disappointing results: Squalamine Eye Drops failed to [...]

2021-11-07T17:53:42+00:00January 24th, 2017|

FDA APPROVES GENENTECH’S LUCENTIS® (RANIBIZUMAB INJECTION) PREFILLED SYRINGE

Lucentis prefilled syringe offers a ready-to-use option to deliver treatment with fewer steps First anti-VEGF prefilled syringe FDA-approved to treat people with wet age-related macular degeneration and people with macular edema after retinal vein occlusion SOUTH SAN FRANCISCO, Calif. – October 14, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: [...]

2021-11-07T17:53:42+00:00October 19th, 2016|